New pill aims to tame chronic hepatitis b
NCT ID NCT05960240
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests AB-101, an oral drug that blocks a protein called PD-L1 to help the immune system fight the hepatitis B virus. The study involves 128 people, including healthy volunteers and patients with chronic hepatitis B. Researchers are primarily checking for safety and how the body processes the drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AB-101 (an oral PD-L1 inhibitor)
What this could lead to
If successful, this could lead to a new treatment option for chronic hepatitis B, potentially reducing the need for lifelong medication.
What could go wrong
This is an early Phase 1 trial focused on safety, not effectiveness. The drug may cause immune-related side effects and may not work as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ASST Papa Giovanni XXIII -Osepedale
Bergamo, Italy
-
Clinial Republican Hospital "Timofei Mosneaga"
Chisinau, Moldova
-
Clinical Republican Hospital "Timofei Mosneaga", ARENSIA E. M.
Bucharest, Romania
-
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
Milan, Italy
-
Municipal Non-Profit Enterprise Kyiv City Clinical Hospital No12 Executive Body of Kyiv City Council
Kyiv, Ukraine
-
National University Hospital
Singapore, Singapore
-
New Zealand Clinical Research Auckland
Grafton, Auckland, New Zealand
-
Prince of Wales Hospital
Hong Kong, Hong Kong, Hong Kong
-
Queen Mary Hospital - PPDS
Hong Kong, Hong Kong, Hong Kong
-
Singapore General Hospital
Singapore, Singapore